Carsgen's satri-cel abstract available on asco website

Shanghai , may 22, 2025 /prnewswire/ -- carsgen therapeutics holdings limited (stock code: 2171.hk), a company focused on developing innovative car t-cell therapies, announces that an abstract of the research results of the confirmatory phase ii clinical trial of satricabtagene autoleucel ("satri-cel", ct041) (an autologous car t-cell product candidate against protein claudin18.2) for advanced gastric/gastroesophageal junction cancer (g/gejc) in china (ct041-st-01, nct04581473) is available on the american society of clinical oncology ("asco") website. title claudin18.2-specific car t cells (satri-cel) versus treatment of physician's choice (tpc) for previously treated advanced gastric or gastroesophageal junction cancer (g/gejc): primary results from a randomized, open-label, phase ii trial (ct041-st-01) abstract number 4003 session type and title oral abstract session – gastrointestinal cancer— gastroesophageal, pancreatic, and hepatobiliary session date and time may 31, 2025, 3:00–6:00 pm cdt this open-label, multicenter, randomized controlled trial (rct) was conducted in china to compare the efficacy and safety of satri-cel versus standard of care (soc) in cldn18.2 positive, advanced g/gejc patients with failure to at least 2 prior lines of treatment.
CAR Ratings Summary
CAR Quant Ranking